J L Cummings

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Cholinesterase inhibitors: A new class of psychotropic compounds
    J L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Am J Psychiatry 157:4-15. 2000
  2. ncbi request reprint Neuropsychiatric assessment of Alzheimer's disease and related dementias
    J L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095 1769, USA
    Aging (Milano) 13:240-6. 2001
  3. ncbi request reprint Regression to the mean: implications for clinical trials of psychotropic agents in dementia
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Alzheimer Res 1:323-8. 2004
  4. ncbi request reprint Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations
    Jeffrey L Cummings
    Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Am J Geriatr Psychiatry 11:131-45. 2003
  5. ncbi request reprint Alzheimer disease
    Jeffrey L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    JAMA 287:2335-8. 2002
  6. ncbi request reprint Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis
    J L Cummings
    Departments of Neurology and Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles CA 90095 1769, USA
    Neurobiol Aging 21:845-61. 2000
  7. ncbi request reprint Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles 90095 1769, USA
    Am J Psychiatry 161:532-8. 2004
  8. ncbi request reprint Alzheimer's disease and its management in the year 2010
    J L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, 90095 1769, USA
    Psychiatr Serv 50:1173-7. 1999
  9. ncbi request reprint Behavioral differences between frontotemporal dementia and Alzheimer's disease: a comparison on the BEHAVE-AD rating scale
    M F Mendez
    Department of Neurology, University of California at Los Angeles, USA
    Int Psychogeriatr 10:155-62. 1998
  10. ncbi request reprint Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003

Detail Information

Publications128 found, 100 shown here

  1. ncbi request reprint Cholinesterase inhibitors: A new class of psychotropic compounds
    J L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Am J Psychiatry 157:4-15. 2000
    ..This article reviews evidence indicating that acetylcholinesterase inhibitors have psychotropic properties...
  2. ncbi request reprint Neuropsychiatric assessment of Alzheimer's disease and related dementias
    J L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095 1769, USA
    Aging (Milano) 13:240-6. 2001
    ..Evaluation of neuropsychiatric symptoms is a critical aspect of dementia diagnosis and management...
  3. ncbi request reprint Regression to the mean: implications for clinical trials of psychotropic agents in dementia
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Curr Alzheimer Res 1:323-8. 2004
    ..Research design adjustments such as collection of both screening and baseline measures to determine eligibility may limit the effects of regression to the mean on trial outcomes and reduce this challenge to clinical trials...
  4. ncbi request reprint Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations
    Jeffrey L Cummings
    Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Am J Geriatr Psychiatry 11:131-45. 2003
    ..Clinical-trial populations differ substantially from unselected populations of AD patients, and these selection biases demand that efficacy data from clinical trials be generalized with caution...
  5. ncbi request reprint Alzheimer disease
    Jeffrey L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    JAMA 287:2335-8. 2002
  6. ncbi request reprint Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis
    J L Cummings
    Departments of Neurology and Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Reed Neurological Research Center, 710 Westwood Plaza, Los Angeles CA 90095 1769, USA
    Neurobiol Aging 21:845-61. 2000
    ..There are a plethora of opportunities for basic scientists to offer insights, develop strategies, and provide techniques and technologies relevant to understanding the clinical manifestations of AD...
  7. ncbi request reprint Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles 90095 1769, USA
    Am J Psychiatry 161:532-8. 2004
    ....
  8. ncbi request reprint Alzheimer's disease and its management in the year 2010
    J L Cummings
    Department of Neurology, University of California, Los Angeles, School of Medicine, 90095 1769, USA
    Psychiatr Serv 50:1173-7. 1999
    ....
  9. ncbi request reprint Behavioral differences between frontotemporal dementia and Alzheimer's disease: a comparison on the BEHAVE-AD rating scale
    M F Mendez
    Department of Neurology, University of California at Los Angeles, USA
    Int Psychogeriatr 10:155-62. 1998
    ..The assessment of neuropsychiatric symptoms with a standardized scale or inventory can help distinguish dementia patients with FTD and AD...
  10. ncbi request reprint Frequency and characteristics of anxiety among patients with Alzheimer's disease and related dementias
    Verna R Porter
    Department of Neurology, University of California, Los Angeles, School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 15:180-6. 2003
    ..These data suggest that anxiety is common among patients with diverse forms of dementia. In AD, anxiety is most common in those with more severe cognitive deterioration and an earlier age at onset...
  11. pmc Donepezil delays progression to AD in MCI subjects with depressive symptoms
    P H Lu
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 72:2115-21. 2009
    ..To determine whether the presence of depression predicts higher rate of progression to Alzheimer disease (AD) in patients with amnestic mild cognitive impairment (aMCI) and whether donepezil treatment beneficially affect this relationship...
  12. ncbi request reprint Executive dysfunction in Alzheimer disease
    Margaret M Swanberg
    Department of Neurology, David Geffen School of Medicine at UCLA, 90095 1769, USA
    Arch Neurol 61:556-60. 2004
    ..Executive dysfunction (EDF) is common in Alzheimer disease (AD); however, its relationship to other symptoms is difficult to assess in patients with AD...
  13. ncbi request reprint ADCS Prevention Instrument Project: development of a brief verbal memory test for primary prevention clinical trials
    David P Salmon
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0948, USA
    Alzheimer Dis Assoc Disord 20:S139-46. 2006
    ....
  14. ncbi request reprint Dementia with leukoaraiosis: clinical differentiation by temporoparietal hypometabolism on (18)FDG-PET imaging
    M F Mendez
    Psychiatry, VA Greater Los Angeles Healthcare System, UCLA School of Medicine, Los Angeles, CA 90073, USA
    Dement Geriatr Cogn Disord 10:518-25. 1999
    ..Copyrightz1999S.KargerAG,Basel..
  15. pmc Cerebral correlates of psychotic symptoms in Alzheimer's disease
    M S Mega
    Department of Neurology UCLA School of Medicine, UCLA School of Medicine, Los Angeles, California, USA
    J Neurol Neurosurg Psychiatry 69:167-71. 2000
    ..Psychotic symptoms are produced by distributed neuronal dysfunction. Abnormalities of reality testing and false inference implicate frontal lobe abnormalities...
  16. ncbi request reprint Dementia with parkinsonism: what is the diagnosis?
    Mei S Chong
    Department of Neurology, The David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 1:41-4. 2004
    ..The 72-year-old patient whose case is reviewed here had abnormalities in all three domains...
  17. ncbi request reprint Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms
    Tzung J Hwang
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 18:17-21. 2004
    ..Psychotic symptoms are significantly more common in the early stage of AD than in MCI. These results are derived from a limited clinical sample and require confirmation in longitudinal community-based investigations...
  18. ncbi request reprint Dementia and neurodevelopmental predisposition: cognitive dysfunction in presymptomatic subjects precedes dementia by decades in frontotemporal dementia
    D H Geschwind
    Department of Neurology, University of California at Los Angeles School of Medicine, 90095 1769, USA
    Ann Neurol 50:741-6. 2001
    ....
  19. ncbi request reprint Gender-related cognitive deficits in Alzheimer's disease
    S McPherson
    Alzheimer s Disease Center, Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095 1769, USA
    Int Psychogeriatr 11:117-22. 1999
    ..Results indicated the presence of gender-related cognitive deficits on tasks of confrontation naming, expressive word knowledge, and both episodic and semantic memory for women with AD, relative to findings in men...
  20. ncbi request reprint Frontotemporal dementia versus vascular dementia: differential features on mental status examination
    M M Cherrier
    Department of Neurology, University of California, Los Angeles School of Medicine, USA
    J Am Geriatr Soc 45:579-83. 1997
    ..The purpose of this study was to elucidate distinct cognitive profiles of a large group of FTD and VaD patients on a brief, clinical mental status examination...
  21. ncbi request reprint Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy
    P L Di Patre
    Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Medical Center, 90095 1732, USA
    Arch Neurol 56:1254-61. 1999
    ....
  22. ncbi request reprint Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease
    J L Cummings
    Reed Neurological Research Center, University of California at Los Angeles, 90095-1769, USA
    J Geriatr Psychiatry Neurol 14:101-8. 2001
    ..Metrifonate significantly reduced many of the psychiatric and behavioral symptoms of AD. The observations suggest that enhancement of cholinergic functions in AD has beneficial effects on behavior...
  23. ncbi request reprint Neuropathologic correlates of activities of daily living in Alzheimer disease
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:56-9. 2006
    ..Deteriorating activities of daily living in Alzheimer Disease subjects correlate with greater overall pathologic burden and possibly selectively with involvement of the medial temporal, occipital, and orbital frontal regions...
  24. ncbi request reprint Early-onset Alzheimer's disease is associated with greater pathologic burden
    Gad A Marshall
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    J Geriatr Psychiatry Neurol 20:29-33. 2007
    ..This suggests that late-onset AD patients have less cognitive reserve than early-onset patients and require fewer pathologic changes to exhibit cognitive deterioration...
  25. ncbi request reprint Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies
    Jeffrey L Cummings
    Department of Neurology, UCLA School of Medicine, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 13:67-73. 2002
    ..This study sought to determine whether patients with dementia with Lewy bodies (DLB) and psychosis responded to treatment with olanzapine...
  26. ncbi request reprint Cognitive and metabolic responses to metrifonate therapy in Alzheimer disease
    M S Mega
    Department of Neurology, University of California at Los Angeles School of Medicine, 90095-1769, USA
    Neuropsychiatry Neuropsychol Behav Neurol 14:63-8. 2001
    ..CONCLUSION: The clinical benefits observed in AD with cholinesterase inhibitor therapy are associated with a metabolic increase of heteromodal cognitive and medial temporal networks...
  27. ncbi request reprint Functional correlates of musical and visual ability in frontotemporal dementia
    B L Miller
    Department of Neurology, University of California at San Francisco School of Medicine, USA
    Br J Psychiatry 176:458-63. 2000
    ..The emergence of new skills in the setting of dementia suggests that loss of function in one brain area can release new functions elsewhere...
  28. ncbi request reprint Treatment of Alzheimer's disease: current and future therapeutic approaches
    Jeffrey L Cummings
    Department of Neurology, University of California, The David Geffen School of Medicine, Los Angeles, CA, USA
    Rev Neurol Dis 1:60-9. 2004
    ..Improved methodologies for clinical trial design and analysis and the development of biological markers may hasten the identification of effective treatments for AD...
  29. ncbi request reprint Positron emission tomography metabolic correlates of apathy in Alzheimer disease
    Gad A Marshall
    Department of Neurology, University of California, Los Angeles, CA, USA
    Arch Neurol 64:1015-20. 2007
    ....
  30. ncbi request reprint Guidelines for managing Alzheimer's disease: part I. Assessment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2263-72. 2002
    ..Suggestions for easily administered and scored assessment tools are provided, and practical tips are given for supporting primary caregivers, thereby increasing efficiency and quality of care for patients with Alzheimer's disease...
  31. ncbi request reprint Utility of clinical criteria in differentiating frontotemporal lobar degeneration (FTLD) from AD
    Howard J Rosen
    Department of Neurology, Memory and Aging Center, University of California at San Francisco, 350 Parnassus Avenue, Suite 800, San Francisco, CA 94143 1207, USA
    Neurology 58:1608-15. 2002
    ..To assess the ability of the current diagnostic criteria for frontotemporal lobar degeneration (FTLD) to differentiate FTLD from AD...
  32. pmc Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
    G W Small
    Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Proc Natl Acad Sci U S A 97:6037-42. 2000
    ..These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments...
  33. ncbi request reprint Cortical change in Alzheimer's disease detected with a disease-specific population-based brain atlas
    P M Thompson
    Laboratory of Neuro Imaging, Department of Neurology, Division of Brain Mapping and Alzheimer s Disease Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Cereb Cortex 11:1-16. 2001
    ..These deficits can therefore be (i) charted in a living population and (ii) compared across individuals and groups, facilitating longitudinal, genetic and interventional studies of dementia...
  34. ncbi request reprint Treatment of Alzheimer's disease
    J L Cummings
    UCLA Alzheimer's Disease Center, UCLA School of Medicine, Los Angeles, California, USA
    Clin Cornerstone 3:27-39. 2001
    ..The 3Rs--repeat, reassure, and redirect--can help caregivers reduce behavioral disturbances in patients with AD and limit the need for pharmacologic management...
  35. ncbi request reprint Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome
    D H Silverman
    Ahmanson Biological Imaging Center, CHS AR 144, Department of Molecular and Medical Pharmacology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095 6942, USA
    JAMA 286:2120-7. 2001
    ..Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined...
  36. ncbi request reprint Treatment of Alzheimer's disease: the role of symptomatic agents in an era of disease-modifying therapies
    Jeffrey L Cummings
    Departmentsof Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Rev Neurol Dis 4:57-62. 2007
    ..Therapeutic regimens for the treatment of AD will include both disease-modifying and symptomatic agents...
  37. pmc Association of GSK3B with Alzheimer disease and frontotemporal dementia
    Barbara A J Schaffer
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, 2506 Gonda, 695 Charles E Young Dr S, Los Angeles, CA 90095 1761, USA
    Arch Neurol 65:1368-74. 2008
    ..As a known tau kinase, GSK3B is a promising candidate gene in the remaining cases of FTD and in AD, for which tau mutations have not been found...
  38. ncbi request reprint Guidelines for managing Alzheimer's disease: Part II. Treatment
    Jeffrey L Cummings
    University of California, Los Angeles, School of Medicine, USA
    Am Fam Physician 65:2525-34. 2002
    ..Throughout the course of the disease, routine use of community resources allows care to be provided by a network of professionals, many of whom will be specialists in Alzheimer's disease...
  39. ncbi request reprint Creativity and dementia: emerging diagnostic and treatment methods for Alzheimer's disease
    Jeffrey L Cummings
    UCLA Alzheimer s Disease Research Center, University of California, Los Angeles, CA, USA
    CNS Spectr 13:1-20; quiz 22. 2008
    ..Debra Cherry, PhD, discusses the advocacy needs of Alzheimer's disease patients and their caregivers. In addition, Patricia Utermohlen, MA, provides a testimonial of the impact of Alzheimer's disease on an accomplished artist...
  40. ncbi request reprint The prevalence and correlates of neuropsychiatric symptoms in a population with Parkinson's disease in Mexico
    John M Ringman
    Department of Neurology, UC Irvine School of Medicine, Irvine, California, USA
    Neuropsychiatry Neuropsychol Behav Neurol 15:99-105. 2002
    ..To study the incidence of behavioral abnormalities in patients with Parkinson's disease (PD) and extend them to a Mexican population...
  41. ncbi request reprint Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease
    S Tekin
    Department of Neurology, UCLA School of Medicine, Los Angeles, CA 90095, USA
    Ann Neurol 49:355-61. 2001
    ..01). These observations suggest that agitation and aberrant motor behavior are correlates of greater NFT pathology in the orbitofrontal cortex in AD, whereas increasing apathy may relate to greater NFT burden in the anterior cingulate...
  42. ncbi request reprint Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades
    D V Jeste
    University of California, San Diego, VA San Diego Healthcare System, 92161, USA
    Arch Gen Psychiatry 56:848-53. 1999
    ..New methods of clinical and research training involving specialists, primary care clinicians, and the lay public are warranted...
  43. ncbi request reprint Executive dysfunction in Alzheimer's disease: association with neuropsychiatric symptoms and functional impairment
    S T Chen
    Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, USA
    J Neuropsychiatry Clin Neurosci 10:426-32. 1998
    ..Executive skills deficits, neuropsychiatric symptoms, and functional disability may emerge from shared neurobiological mechanisms...
  44. ncbi request reprint The spectrum of behavioral responses to cholinesterase inhibitor therapy in Alzheimer disease
    M S Mega
    Laboratory of Neuro Imaging, Alzheimer s Disease Research Center, University of California, Los Angeles, School of Medicine, 90095 1769, USA
    Arch Neurol 56:1388-93. 1999
    ..Characterizing the pretreatment profile of patients who are likely to respond to cholinergic therapy will aid the efficient use of clinical resources...
  45. ncbi request reprint Activities of daily living in Alzheimer's disease: neuropsychiatric, cognitive, and medical illness influences
    S Tekin
    Department of Neurology, Alzheimer Disease Research Center, and Department of Psychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, CA, USA
    Am J Geriatr Psychiatry 9:81-6. 2001
    ..IADLs changed with cognition and neuropsychiatric disturbances in AD. Medical illness burden had little influence on functional status and a limited impact on neuropsychiatric symptoms...
  46. ncbi request reprint MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects
    G Bartzokis
    North Little Rock VA Medical Center, Department of Psychiatry, University of Arkansas for Medical Sciences, 72114, USA
    Magn Reson Imaging 17:213-22. 1999
    ..The FDRI results suggest that disregulation of iron metabolism occurs in PD and that this disregulation may differ in earlier- versus later-onset PD...
  47. ncbi request reprint Multiple system atrophy presenting with language impairment
    L G Apostolova
    Department of Neurology, University of California Los Angeles, USA
    Neurology 67:726-7. 2006
  48. doi request reprint Biochemical markers in persons with preclinical familial Alzheimer disease
    J M Ringman
    UCLA Department of Neurology, Alzheimer Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Neurology 71:85-92. 2008
    ..Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease...
  49. pmc 3D mapping of language networks in clinical and pre-clinical Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Brain Lang 104:33-41. 2008
    ..Using a novel 3D mapping technique, we demonstrated that in AD language abilities are strongly influenced by the integrity of the perisylvian cortical regions...
  50. ncbi request reprint 3D mapping of mini-mental state examination performance in clinical and preclinical Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Alzheimer Dis Assoc Disord 20:224-31. 2006
    ..As a global cognitive measure, MMSE depends on the integrity of widely distributed cortical areas in both brain hemispheres with left-sided predominance...
  51. ncbi request reprint ADCS Prevention Instrument Project: behavioral measures in primary prevention trials
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Alzheimer Dis Assoc Disord 20:S147-51. 2006
    ..Experimental behavioral measures were included in the protocol to examine this hypothesis...
  52. ncbi request reprint Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    Am J Geriatr Psychiatry 14:605-12. 2006
    ..The authors report the effects of donepezil on behavioral disturbances in patients with relatively severe psychopathology at baseline...
  53. ncbi request reprint 3D comparison of hippocampal atrophy in amnestic mild cognitive impairment and Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine UCLA, CA, USA
    Brain 129:2867-73. 2006
    ..Novel hippocampal analytic techniques that can track the spread of hippocampal pathology in 3D with such precision are a promising research tool...
  54. ncbi request reprint Treatments for behavioural disorders in neurodegenerative diseases: drug development strategies
    Jeffrey L Cummings
    Department of Neurology, 710 Westwood Plaza, David Geffen School of Medicine, UCLA, Los Angeles, California 90095, USA
    Nat Rev Drug Discov 5:64-74. 2006
    ....
  55. ncbi request reprint Neuropsychiatric and behavioral symptoms in a community sample of Hispanics with Alzheimer's disease
    Freddy Ortiz
    The Neuropsychiatry Research Memory Clinic, Olive View UCLA Medical Center, Sylmar, CA 91342, USA
    Am J Alzheimers Dis Other Demen 21:263-73. 2006
    ..These findings have implications for differential sociocultural presentations of Alzheimer's disease among ethnic/racial groups...
  56. ncbi request reprint Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    Neurology 67:57-63. 2006
    ..To investigate the behavioral effects of memantine in moderate to severe Alzheimer disease (AD)...
  57. ncbi request reprint Clinical evaluation as a biomarker for Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, Alzheimer s Disease Research Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    J Alzheimers Dis 8:327-37. 2005
    ..Biomarkers must closely reflect clinical outcomes to be useful as evaluations of disease progression or as outcomes in clinical trials...
  58. ncbi request reprint Deficits in facial emotion processing in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 23:271-9. 2007
    ..Patients with Alzheimer disease consistently demonstrate impaired performance on tests of facial emotion processing. However, it remains unclear how early in the neurodegenerative process these deficits emerge...
  59. ncbi request reprint Effective pharmacologic management of Alzheimer's disease
    Martin R Farlow
    Department of Neurology, Indiana University School of Medicine, Indianapolis 46202 5111, USA
    Am J Med 120:388-97. 2007
    ....
  60. doi request reprint Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 29:406-12. 2010
    ..This was a hypothesis-forming study, designed to provide a basis for possible future research...
  61. pmc Integrating ADNI results into Alzheimer's disease drug development programs
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, United States
    Neurobiol Aging 31:1481-92. 2010
    ....
  62. pmc 3D comparison of low, intermediate, and advanced hippocampal atrophy in MCI
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, CA, USA
    Hum Brain Mapp 31:786-97. 2010
    ..Greater CA1 and subicular atrophy can be demonstrated early and is predictive of future conversion to AD, whereas CA2-3 involvement becomes more evident as the disease progresses...
  63. pmc Automated 3D mapping of baseline and 12-month associations between three verbal memory measures and hippocampal atrophy in 490 ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, CA 90095, USA
    Neuroimage 51:488-99. 2010
    ..After controlling for baseline hippocampal atrophy, memory performance showed regionally specific associations with hippocampal radial distance in predominantly CA1 but also in subicular distribution...
  64. doi request reprint Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Clin Drug Investig 30:41-9. 2010
    ..The aim of the component of the trial reported here was to evaluate the skin tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate AD...
  65. doi request reprint Defining and labeling disease-modifying treatments for Alzheimer's disease
    Jeffrey L Cummings
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 5:406-18. 2009
    ..Prevention claims will depend heavily on biomarker outcomes...
  66. pmc Current concepts of mild cognitive impairment and their applicability to persons at-risk for familial Alzheimer's disease
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research at UCLA, Associate Clinical Professor, UCLA Department of Neurology, 10911 Weyburn Ave, 200, Los Angeles, CA 90095 7226, USA
    Curr Alzheimer Res 6:341-6. 2009
    ..The study of FAD provides an opportunity to test various criteria for early AD and these observations should be taken into consideration in future iterations of such diagnostic criteria...
  67. pmc Surface feature-guided mapping of cerebral metabolic changes in cognitively normal and mildly impaired elderly
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, 10911 Weyburn Avenue, Los Angeles, CA 90095, USA
    Mol Imaging Biol 12:218-24. 2010
    ..The aim of this study was to investigate the longitudinal positron emission tomography (PET) metabolic changes in the elderly...
  68. pmc Controversies in Alzheimer's disease drug development
    Jeffrey L Cummings
    Departments of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Int Rev Psychiatry 20:389-95. 2008
    ..The questions surrounding these issues must be resolved as disease-modifying therapies for AD are advanced. These controversies are framed and potential directions towards resolution described...
  69. doi request reprint Behavioral effects of current Alzheimer's disease treatments: a descriptive review
    Jeffrey L Cummings
    UCLA Alzheimer Disease Center, UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:49-60. 2008
    ....
  70. pmc Diagnosing depression in Alzheimer disease with the national institute of mental health provisional criteria
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90073, USA
    Am J Geriatr Psychiatry 16:469-77. 2008
    ....
  71. pmc Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative
    Jeffrey L Cummings
    Department of Neurology, The Mary S Easton Center for Alzheimer s Disease Research at UCLA, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Alzheimers Dis 19:375-88. 2010
    ..The Center supports excellent senior 3 investigators and serves as an incubator for new scientists, agents, models, technologies and concepts that will significantly influence the future of AD treatment and AD research...
  72. ncbi request reprint Neuropsychiatric manifestations in mild cognitive impairment: a systematic review of the literature
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, UCLA, USA
    Dement Geriatr Cogn Disord 25:115-26. 2008
    ..MCI is an important risk state for dementia. Neuropsychiatric symptoms may be present in MCI...
  73. pmc Three-dimensional gray matter atrophy mapping in mild cognitive impairment and mild Alzheimer disease
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, 10911 Westwood Blvd, Second Floor, Los Angeles, CA 90095, USA
    Arch Neurol 64:1489-95. 2007
    ..Most patients with MCI harbor the pathologic changes of AD and demonstrate transition to dementia at a rate of 10% to 15% per year. Patients with AD and MCI experience progressive brain atrophy...
  74. ncbi request reprint Neuropsychiatric symptoms are associated with progression from mild cognitive impairment to Alzheimer's disease
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 24:253-9. 2007
    ..Depression and apathy may identify a subset of MCI subjects at higher risk of progression to Alzheimer's disease (AD). However, it remains uncertain whether a broader spectrum of psychopathology is associated with progression to AD...
  75. pmc 3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects
    Liana G Apostolova
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
    Neurobiol Aging 31:1284-303. 2010
    ..p-tau(181) showed stronger correlation in ApoE4 carriers, while t-tau showed stronger correlation in ApoE4 noncarriers. Of the 3 PIB measures the precuneal SUVR showed strongest associations with hippocampal atrophy...
  76. ncbi request reprint Neuropathologic correlates of apathy in Alzheimer's disease
    Gad A Marshall
    Department of Neurology, University of California at Los Angeles, Reed Neurological Research Center, 2 238, 710 Westwood Plaza, CA 90095 1769, USA
    Dement Geriatr Cogn Disord 21:144-7. 2006
    ..01, and r = 0.438, p = 0.032). This analysis suggests that chronic apathy in AD correlates with a greater anterior cingulate NFT burden and that chronic behavioral changes are more reflective than acute changes of disease pathology...
  77. ncbi request reprint Relational integration and executive function in Alzheimer's disease
    James A Waltz
    Departjment of Psychology, University of California, Los Angeles, CA 90095 1563, USA
    Neuropsychology 18:296-305. 2004
    ....
  78. ncbi request reprint Fluctuations in cognitive function in dementia with Lewy bodies
    Jeffrey L Cummings
    David Geffen School of Medicine, UCLA, Los Angeles, CA, USA
    Lancet Neurol 3:266. 2004
  79. ncbi request reprint Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical "disconnection" in aging and Alzheimer's disease
    George Bartzokis
    Department of Neurology, Univeristy of California School of Medicine, Los Angeles, CA 90095, USA
    Neurobiol Aging 25:843-51. 2004
    ..In AD this process is globally exacerbated, consistent with an extracellular deleterious process such as amyloid beta-peptide toxicity. Non-invasive measures such as R2 may be useful in primary prevention studies of AD...
  80. ncbi request reprint Alzheimer's disease
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1769, USA
    N Engl J Med 351:56-67. 2004
  81. ncbi request reprint Dementia with lewy bodies: molecular pathogenesis and implications for classification
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 17:112-9. 2004
    ..Classification systems based on symptom complexes related to the presence of protein misfolding will assist therapeutic decisions...
  82. ncbi request reprint Subcortical hyperintensities in Alzheimer's disease: associated clinical and metabolic findings
    David L Sultzer
    Departments of Psychiatry and Biobehavioral Sciences, University of California Los Angeles, USA
    J Neuropsychiatry Clin Neurosci 14:262-9. 2002
    ..These preliminary findings indicate that subcortical MRI hyperintensities may play a role in the pathophysiology and clinical expression of Alzheimer's disease...
  83. ncbi request reprint Speech and language in progressive nonfluent aphasia compared with early Alzheimer's disease
    Mario F Mendez
    Department of Neurology, David Geffen School of Medicine, University of California at Los Angeles, USA
    Neurology 61:1108-13. 2003
    ..The differentiation of PA from early Alzheimer's disease (AD) is important, given the presence of early language changes in AD...
  84. ncbi request reprint Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
    Mol Genet Metab 80:350-5. 2003
    ..4). These data indicate that evaluation of brain metabolism by PET in appropriately selected patients may improve the accuracy of clinical prognostic assessment...
  85. pmc A potential role of the curry spice curcumin in Alzheimer's disease
    John M Ringman
    University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
    Curr Alzheimer Res 2:131-6. 2005
    ..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
  86. ncbi request reprint Alzheimer's disease: from molecular biology to neuropsychiatry
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, Reed Neurological Research Center, UCLA School of Medicine, Los Angeles, CA 90095 1769, USA
    Semin Clin Neuropsychiatry 8:31-6. 2003
    ..The steps of the amyloid cascade present multiple targets for drug development and identification of effective disease-modifying anti-Alzheimer's disease treatments...
  87. ncbi request reprint Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia
    George Bartzokis
    Department of Neurology, The David Geffen School of Medicine at UCLA, USA
    Arch Gen Psychiatry 63:63-72. 2006
    ..This may result in a progressive "disconnection" of widely distributed neural networks that may underlie the age risk factor for AD...
  88. ncbi request reprint Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men
    Po H Lu
    Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles, USA
    Arch Neurol 63:177-85. 2006
    ..There is a compelling need for therapies that prevent, defer the onset, slow the progression, or improve the symptoms of Alzheimer disease (AD)...
  89. pmc Subtle deficits in instrumental activities of daily living in subtypes of mild cognitive impairment
    Edmond Teng
    Neurobehavior Unit, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA 90073, USA
    Dement Geriatr Cogn Disord 30:189-97. 2010
    ..We explored the relationship between these factors by comparing instrumental activities of daily living (IADLs) among cognitive subtypes of MCI and examining associations between IADL and neuropsychological indices...
  90. ncbi request reprint Behavioral and neuropsychiatric outcomes in Alzheimer's disease
    Jeffrey L Cummings
    Alzheimer s Disease Research Center, Department of Neurology, University of California Los Angeles, 710 Westwood Plaza Rm 2 238, Los Angeles, CA 90095, USA
    CNS Spectr 10:22-5. 2005
    ....
  91. ncbi request reprint Apathy and executive function in Alzheimer's disease
    Susan McPherson
    Alzheimer s Disease Center, Department of Neurology, UCLA School of Medicine, Los Angeles, California 90095 1769, USA
    J Int Neuropsychol Soc 8:373-81. 2002
    ..Neuropsychological measures not dependent on executive functions were unrelated to apathy. Apathy is associated with executive dysfunction and not with other neuropsychological deficits. Apathy is distinct from dysphoria...
  92. ncbi request reprint Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations
    John M Ringman
    UCLA Department of Neurology, Alzheimer s Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Brain 130:1767-76. 2007
    ..Decreased FA in of the columns of the fornix is particularly robust in early FAD and may provide a biomarker for early disease in sporadic Alzheimer's disease...
  93. doi request reprint Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers
    John M Ringman
    Alzheimer s Disease Research Center, UCLA, Los Angeles, CA 90095 7226, USA
    Dement Geriatr Cogn Disord 25:380-4. 2008
    ..In our study we compared the prevalence of headaches between nondemented FAD mutation carriers (MCs) and non-mutation-carrying controls (NCs)...
  94. pmc Persistence of neuropsychological testing deficits in mild cognitive impairment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, Calif, USA
    Dement Geriatr Cogn Disord 28:168-78. 2009
    ....
  95. ncbi request reprint Delusional thoughts and regional frontal/temporal cortex metabolism in Alzheimer's disease
    David L Sultzer
    Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, USA
    Am J Psychiatry 160:341-9. 2003
    ..In this study the authors examined the relationship between delusional thoughts and regional cortical metabolism in patients with Alzheimer's disease...
  96. ncbi request reprint Disease-modifying therapies for Alzheimer disease: challenges to early intervention
    Jeffrey L Cummings
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Neurology 69:1622-34. 2007
    ..The neurologic health of the growing aging population demands disease-modifying therapies and the development of methods to identify and test promising candidate agents...
  97. ncbi request reprint Structural correlates of apathy in Alzheimer's disease
    Liana G Apostolova
    Department of Neurology, Laboratory of Neuro Imaging, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
    Dement Geriatr Cogn Disord 24:91-7. 2007
    ..Apathy is the most common noncognitive symptom in Alzheimer's disease (AD). The structural correlates of apathy in AD have not yet been described...
  98. doi request reprint Optimizing phase II of drug development for disease-modifying compounds
    Jeffrey L Cummings
    Department of Neurology and Psychiatry, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Alzheimers Dement 4:S15-20. 2008
    ..in a successful drug development program; all have some promise for reforming phase II and answering the central question of "how much information is sufficient to proceed to phase III without excessive risk for failure?"..
  99. ncbi request reprint White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study
    George Bartzokis
    Department of Neurology, Alzheimer s Disease Center, University of California, Los Angeles, 710 Westwood Plaza, Room 2 238, Los Angeles, CA 90095 1769, USA
    Arch Neurol 60:393-8. 2003
    ..6 years and then declines. Postmortem evidence indicates that the structural integrity of myelin sheaths deteriorates during normal aging, especially in late myelinating regions such as the frontal lobes...
  100. ncbi request reprint Brain ferritin iron as a risk factor for age at onset in neurodegenerative diseases
    George Bartzokis
    Department of Neurology, UCLA, Los Angeles, California, USA
    Ann N Y Acad Sci 1012:224-36. 2004
    ..In vivo MRI can measure and track brain ferritin iron levels and provides an opportunity to design therapeutic interventions that target high-risk populations early in the course of illness, possibly even before symptoms appear...
  101. doi request reprint Current therapeutic targets for the treatment of Alzheimer's disease
    Joshua D Grill
    Mary S Easton Center for Alzheimer s Disease Research, Deane F Johnson Center for Neurotherapeutics, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Expert Rev Neurother 10:711-28. 2010
    ..We provide a review of these targets for drug development...